Publication

Research Papers : 2016

• Hepatic dipeptidyl peptidase-4 controls pharmacokinetics of vildagliptin in vivo.
  Asakura, M.; Fukami, T.; Nakajima, M.; Fujii, H.; Atsuda, K.; Itoh, T.; Fujiwara, R.
  Drug Metab. Dispos., 2017, 4, 237.
• Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.
  Asakura, M.; Karaki, F.; Fujii, H.; Atsuda, K.; Itoh, T.; Fujiwara, R.
  Sci. Rep., 2016, 6, 35633.
• MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells.
  Yamashita, Y.; Asakura, M.; Mitsugi, R.; Fujii, H.; Nagai, K.; Atsuda, K.; Itoh, T.; Fujiwara, R.
  Drug Metab. Pharmacokinet., 2016, 31, 201−209.
• Narcolepsy-like sleep disturbance in orexin knockout mice are normalized by the 5-HT_1A receptor agonist 8-OH-DPAT.
  Mori, T.; Uzawa, N.; Iwase, Y.; Masukawa, D.; Rahmadi, M.; Hirayama, S.; Hokazono, M.; Higashiyama, K.; Shioda, S.; Suzuki, T.
  Psychopharmacology, 2016, 233, 2324-2353.
• Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
  Ishikawa, K.; Mochizuki, Y.; Hirayama, S.; Nemoto, T.; Itoh, K.; Fujii, H.
  Bioorg. Med. Chem., 2016, 24, 2199-2205.